Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)
Open Access
- 14 November 2025
- Vol. 10 (11) , 105878
Abstract
No abstract availableKeywords
Funding Information
- Esteve Pharmaceuticals
- Novartis
This publication has 77 references indexed in Scilit:
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?Journal of Clinical Oncology, 2007
- Dosimetry For 90 Y-DOTATOC Therapies in Patients with Neuroendocrine TumorsCancer Biotherapy and Radiopharmaceuticals, 2007
- Serum Gastrin in Zollinger-Ellison SyndromeMedicine, 2006
- Serum Gastrin in Zollinger-Ellison SyndromeMedicine, 2006
- Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsJournal of Clinical Oncology, 2005
- Treatment with cisplatin and etoposide in patients with neuroendocrine tumorsCancer, 2001
- Discriminating Capacity of Indole Markers in the Diagnosis of Carcinoid TumorsClinical Chemistry, 2000
- Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatinBritish Journal of Cancer, 1999
- Chromogranin A: Its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker*Endocrine Reviews, 1991